Eyes on JP Morgan Healthcare Conference The largest healthcare investment symposium will be held in San Francisco in January 2020
Translated by Kim So-in 공개 2019-11-22 08:00:00
이 기사는 2019년 11월 22일 08:00 thebell 에 표출된 기사입니다.
The annual JP Morgan Healthcare Conference, the largest healthcare investment symposium in the world, will be held early next year. Market is paying keen attention to newcomers to the event.The JP Morgan Healthcare Conference has grown into a global event with more than 9000 attendees and more than 450 private and public companies. The conference began in 1983 and next year will mark its 38th event. Unlike BIO International Convention which takes place in June every year, the JP Morgan Health Conference is an investor meeting-oriented event. As the event is held in January every year, the conference is viewed as the event that presents most up-do-date information and promising companies of the entire healthcare landscape of the year.
The 38th JP Morgan Healthcare Conference will take place from January 13 to 16, 2020 at Westin St. Francis Hotel San Francisco, California. Detailed schedule and program of the event haven't been released yet. Microsoft co-founder, former CEO and current co-chair of the Bill & Melinda Gates Foundation Bill Gates gave a speech at this year's conference.
Unlike other healthcare conferences, the JP Morgan Healthcare Conference is for clients of the firm, by invitation only. Among domestic biotech firms, Green Cross attended the event for the first time in 2011. The total number of domestic attendees rose from 21 firms in 2016 to 50 firms this year.
Samsung Biologics, Celltrion, LG Chem Life Sciences Company, Hanmi Pharm, Daewoong Pharmaceutical, Medytox, Hugel, Genexine, SCM Lifescience, and ABL Bio reportedly received official invitations for the next year's conference. Samsung Biologics and Celltrion, which have participated in the event since 2012 will present their business plans. It is not yet known whether Celltrion Chairman Seo Jung-jin will deliver a presentation himself next year.
SCM Lifescience, led by former Green Cross president Rhee Byung-geon, is likely to focus on one-on-one meetings instead of presentations. Helixmith and Kolon TissueGene which attended this year's conference are not on the next year's attendee list. A cell-based biotechnology company Biosolution will continue discussion with investors at the event regarding clinical trials on osteoarthritis cell therapy CartiLife.
"As the event will gather all investors from every corner of the world, it is crucial to form partnerships with a variety of companies," said a biotechnology company official.
(By reporter Min Kyung-moon)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
best clicks
최신뉴스 in 전체기사
-
- 경남제약 품는 휴마시스, 유통네트워크·진단키트 '시너지'
- [Company Watch]글로벌텍스프리, 프랑스 자회사 '적자 전환'
- [Red & Blue]'주목도 높아지는 폐배터리' 새빗켐, 침묵 깨고 반등
- [HLB '리보세라닙' 미국 진출기]시장 우려 불식 나선 진양곤, 갑자기 마련된 기자회견
- 효성화학 특수가스 사업부, '경영권 지분 매각'으로 선회
- 한양, 만기도래 회사채 '사모채'로 차환한다
- 동인기연, 'GS 출신' 30년 베테랑 전호철 상무 영입 '성장 방점'
- 에스트래픽, 적자 '일시적 현상'... 2분기 수익개선 기대
- [Company Watch]'자회사 회생신청' 투비소프트, 성과 없는 신사업
- '크라우드 펀딩' 와디즈, '테슬라 요건' 상장 추진